Zobrazeno 1 - 10
of 1 207
pro vyhledávání: '"R. Gertler"'
Autor:
Sudo K; The University of Texas MD Anderson Cancer Center, Houston, TX., Elimova E; The University of Texas MD Anderson Cancer Center, Houston, TX., Skinner HD; The University of Texas MD Anderson Cancer Center, Houston, TX., Hofstetter WL; The University of Texas MD Anderson Cancer Center, Houston, TX., Ajani JA; The University of Texas MD Anderson Cancer Center, Houston, TX jajani@mdanderson.org.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2014 Jul 01; Vol. 32 (19), pp. 2112-3. Date of Electronic Publication: 2014 May 27.
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 32(19)
Publikováno v:
Journal of Clinical Oncology. 32:2112-2113
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Zhan, Li1,2 (AUTHOR), Edd, Jon1,3 (AUTHOR) jedd@mgh.harvard.edu, Mishra, Avanish1,2,3 (AUTHOR), Toner, Mehmet1,2,4 (AUTHOR) mtoner@mgh.harvard.edu
Publikováno v:
Advanced Science. 10/28/2024, Vol. 11 Issue 40, p1-14. 14p.
Autor:
So, Kevin Wang Leong1 (AUTHOR) kevinswl@connect.hku.hk, Su, Zezhuo1 (AUTHOR), Cheung, Jason Pui Yin1 (AUTHOR), Choi, Siu-Wai1 (AUTHOR) htswchoi@hku.hk
Publikováno v:
Diagnostics (2075-4418). Oct2024, Vol. 14 Issue 19, p2172. 22p.
Autor:
M. Macguill, G. Wiesner, Jürgen Hörer, Klaus Martin, Manfred Vogt, Alexander Hapfelmeier, R. Gertler, N.P. Mayr, Peter Tassani
Publikováno v:
British journal of anaesthesia. 110(4)
Background Once aprotinin was no longer available for clinical use, ɛ-aminocaproic acid (EACA) and tranexamic acid became the only two options for antifibrinolytic therapy. We compared aprotinin and EACA with respect to their blood-sparing efficacy
Autor:
N.P. Mayr, M. Macguill, Peter Tassani, Christian Schreiber, Manfred Vogt, Klaus Martin, R. Gertler, G. Wiesner, H. Liermann
Publikováno v:
British journal of anaesthesia. 107(6)
Background With the withdrawal of aprotinin from worldwide marketing in November 2007, many institutions treating patients at high risk for hyperfibrinolysis had to update their therapeutic protocols. At our institution, the standard was switched fro
Autor:
G Wiesner, A Sterner, Manfred Vogt, M. Macguill, K Martin, Jürgen Hörer, Christian Schreiber, Peter Tassani, R. Gertler
Publikováno v:
The Thoracic and cardiovascular surgeon. 59(5)
Background e-Aminocaproic acid (EACA) and tranexamic acid (TXA) are used for antifibrinolytic therapy in neonates undergoing cardiac surgery, although data directly comparing their blood-sparing efficacy are not yet available. We compared two consecu
Publikováno v:
The Thoracic and Cardiovascular Surgeon. 59